MA39496A - Inhibiteurs de mtor spécifiques dans le traitement de l'adrénoleucodystrophie liée à l'x - Google Patents
Inhibiteurs de mtor spécifiques dans le traitement de l'adrénoleucodystrophie liée à l'xInfo
- Publication number
- MA39496A MA39496A MA039496A MA39496A MA39496A MA 39496 A MA39496 A MA 39496A MA 039496 A MA039496 A MA 039496A MA 39496 A MA39496 A MA 39496A MA 39496 A MA39496 A MA 39496A
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- linked
- mtor inhibitors
- adrenoleucodystrophy
- specific mtor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6841—In situ hybridisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne de nouvelles utilisations d'inhibiteurs de mtor spécifiques en tant que médicament, en particulier pour le traitement de l'adrénoleucodystrophie à liaison x (x-ald). L'invention concerne également un procédé pour identifier un composé potentiellement utile pour le traitement et / ou la prévention de x-ald.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14382353.2A EP2997977A1 (fr) | 2014-09-19 | 2014-09-19 | Inhibiteurs de MTOR spécifiques dans le traitement d'une adrénoleucodystrophie à liaison X |
Publications (1)
Publication Number | Publication Date |
---|---|
MA39496A true MA39496A (fr) | 2016-03-24 |
Family
ID=51752074
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA039496A MA39496A (fr) | 2014-09-19 | 2015-09-21 | Inhibiteurs de mtor spécifiques dans le traitement de l'adrénoleucodystrophie liée à l'x |
Country Status (7)
Country | Link |
---|---|
US (1) | US10071063B2 (fr) |
EP (2) | EP2997977A1 (fr) |
JP (1) | JP2017529397A (fr) |
CN (1) | CN107206087A (fr) |
CA (1) | CA2961729A1 (fr) |
MA (1) | MA39496A (fr) |
WO (1) | WO2016042166A1 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3335730A1 (fr) * | 2016-12-15 | 2018-06-20 | Fundació Institut de Recerca Biomédica de Bellvitge (IDIBELL) | Composés pour le traitement d'une adrénoleucodystrophie à liaison x |
AU2018390799A1 (en) * | 2017-12-20 | 2020-05-07 | Societe Des Produits Nestle S.A. | Compositions and methods using high protein for induction of autophagy |
EP3727419A1 (fr) * | 2017-12-20 | 2020-10-28 | Société des Produits Nestlé S.A. | Compositions et méthodes utilisant une combinaison d'inducteur d'autophagie et de protéine riche pour l'induction de l'autophagie |
CN108827747A (zh) * | 2018-06-04 | 2018-11-16 | 华中科技大学苏州脑空间信息研究院 | 一种多色荧光标记样本的塑性包埋方法 |
CN115678960B (zh) * | 2022-09-13 | 2024-03-19 | 澳门大学 | 一种缓冲液、试剂盒和蛋白酶体检测方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5262165A (en) | 1992-02-04 | 1993-11-16 | Schering Corporation | Transdermal nitroglycerin patch with penetration enhancers |
US6010715A (en) | 1992-04-01 | 2000-01-04 | Bertek, Inc. | Transdermal patch incorporating a polymer film incorporated with an active agent |
US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
JP3534775B2 (ja) | 1995-06-07 | 2004-06-07 | オーソ―マクニール ファーマシューティカル,インコーポレイテッド | 17−デアセチルノルゲスチマートを単独でまたはエストロゲンと組み合わせて投与するための経皮パッチおよび方法 |
WO1997004810A1 (fr) * | 1995-07-28 | 1997-02-13 | The Regents Of The University Of California | Proteine dax-1, procedes de production et d'utilisation |
US5948433A (en) | 1997-08-21 | 1999-09-07 | Bertek, Inc. | Transdermal patch |
US8029561B1 (en) | 2000-05-12 | 2011-10-04 | Cordis Corporation | Drug combination useful for prevention of restenosis |
AU2001293161B2 (en) * | 2000-09-29 | 2005-03-24 | Ethicon, Inc. | Coatings for medical devices |
ES2303441B1 (es) | 2006-05-05 | 2009-06-22 | Fundacio Privada Institut D`Investigacio Biomedica De Bellvitge (Idibell) | Uso del acido valproico o de una sal farmaceuticamente aceptable del mismo para la prevencion y/o el tratamiento de la adenoleucodistrofia ligada a x. |
TW201035104A (en) | 2009-03-27 | 2010-10-01 | Chunghwa Chemical Synthesis & Biotech Co Ltd | Improved synthesis method for Temsirolimus and its similar compounds |
WO2011066430A2 (fr) * | 2009-11-25 | 2011-06-03 | Duke University | Agents thérapeutiques pour maladies neurodégénératives |
ES2377381B1 (es) * | 2010-05-17 | 2013-03-14 | Fundació Institut De Investigació Biomèdica De Bellvitge (Idibell) | Uso de una combinación de n-acetil-cisteína y ácido lipoico para la preparación de un medicamento útil para el tratamiento de una enfermedad con daño axonal y lesiones oxidativas concomitantes. |
CN103261432A (zh) * | 2010-09-29 | 2013-08-21 | 奥克西雷恩英国有限公司 | 磷酸化的n-聚糖的脱甘露糖基化 |
WO2013071247A1 (fr) * | 2011-11-10 | 2013-05-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Signatures d'expression génétique de la sensibilité d'un néoplasme à un traitement |
-
2014
- 2014-09-19 EP EP14382353.2A patent/EP2997977A1/fr not_active Withdrawn
-
2015
- 2015-09-21 JP JP2017535134A patent/JP2017529397A/ja active Pending
- 2015-09-21 MA MA039496A patent/MA39496A/fr unknown
- 2015-09-21 CN CN201580062585.2A patent/CN107206087A/zh active Pending
- 2015-09-21 EP EP15766167.9A patent/EP3193937A1/fr not_active Withdrawn
- 2015-09-21 US US15/512,392 patent/US10071063B2/en not_active Expired - Fee Related
- 2015-09-21 WO PCT/EP2015/071563 patent/WO2016042166A1/fr active Application Filing
- 2015-09-21 CA CA2961729A patent/CA2961729A1/fr not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2016042166A1 (fr) | 2016-03-24 |
CA2961729A1 (fr) | 2016-03-24 |
JP2017529397A (ja) | 2017-10-05 |
EP2997977A1 (fr) | 2016-03-23 |
CN107206087A (zh) | 2017-09-26 |
EP3193937A1 (fr) | 2017-07-26 |
US10071063B2 (en) | 2018-09-11 |
US20170273915A1 (en) | 2017-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA39496A (fr) | Inhibiteurs de mtor spécifiques dans le traitement de l'adrénoleucodystrophie liée à l'x | |
CY1122994T1 (el) | Μεθοδος καθαρισμου κανναβινοειλων, συνθεσεων και kit αυτων | |
MA43518A (fr) | 3-azabicyclo[3.1.0]hexanes substitués servant d'inhibiteurs de cétohexokinase | |
CL2017002086A1 (es) | Composición hemostática y dispositivo hemostático (variantes) | |
BR112019007977A2 (pt) | composto, composição farmacêutica, método de tratamento ou prevenção de câncer, e, uso de um composto | |
BR112014012878A8 (pt) | composto, uso de um composto, composição farmacêutica e processos de fabricação de um composto | |
CL2015002529A1 (es) | Compuestos de tetrahidropirrolotiazina | |
MA42032A (fr) | Acides 3-aryl-4-amido-bicyclo [4,5,0]hydroxamiques en tant qu'inhibiteurs de hdac | |
WO2015031564A3 (fr) | Composés de la série des 1h-benzo[d]imidazoles substitués à titre d'inhibiteurs de déméthylase 1 spécifique de la lysine (lsd1) | |
EA201690199A1 (ru) | Лекарственное средство для лечения неалкогольной жировой болезни печени | |
FR3029790B1 (fr) | Microbille d'hydrogel de chitosane | |
EA201692285A8 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
MA41977B1 (fr) | Imidazopyrazinones utilisées comme inhibiteurs de pde1 | |
EA201591805A1 (ru) | Оксабицикло [2.2.2] кислоты - модуляторы gpr120 | |
EA201792233A8 (ru) | Способ уменьшения загрязнения поверхностей | |
MA47736B1 (fr) | Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1 | |
CL2015001753A1 (es) | Compuestos derivados de carbamato de ciclohexilo y quinuclidinilo, agonistas beta2 adrenergicos y antagonistas muscarinicos m3; composicion farmaceutica que los comprende; metodo para tratar; y producto de combinacion que comprende a estos compuestos junto a un corticosteroide y/o un inhibidor de pde4. | |
FR3046610B1 (fr) | Utilisation de 4,4-difluoro-4-bora-3a,4a-diaza-s-indacenes pour la securisation | |
MX2016009058A (es) | Compuesto de acido piridilaminoacetico y composicion farmaceutica que contiene aceite de ricino polioxietileno. | |
WO2016094834A3 (fr) | Méthode de traitement d'une affection à médiation par le complément provoquée par un agent infectieux chez un patient | |
PH12017501130A1 (en) | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | |
MA38816A (fr) | Sulfamidase modifiée et sa production | |
MA41634B1 (fr) | Formulation à base de combinaison de tésofensine et de métoprolol | |
MA40366A (fr) | Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines | |
EA201890419A1 (ru) | ОТСЕЛЕКТИРОВАННЫЙ АМИД γ-ГИДРОКСИМАСЛЯНОЙ КИСЛОТЫ И ЕГО ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ ЗЛОУПОТРЕБЛЕНИЯ АЛКОГОЛЕМ |